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Introduction {#sec1}
============

Nuclear factor-kappaB (NF-κB), a potent transcription factor, is highly conserved from insect to human and plays critical roles in a wide variety of physiological and pathological processes, such as memory storage ([@bib23]), immunity and cancer ([@bib35]), neurodegenerative diseases ([@bib33]), and chronic pain ([@bib28]). NF-κB p50/p65/inhibitor of NF-κB (IκB-α) complex is located in the cytoplasm. On activation, both p65 and IκB-α are phosphorylated, and then *p*-IκB-α is degenerated after ubiquitination, whereas phospho-p65 (*p*-p65) is translocated into the nucleus, where it regulates gene transcription ([@bib28]). At present, all the functions of NF-κB are attributed to the transcriptional effect in vertebrate ([@bib29]). There are two NF-κB activation pathways, classical and alternative; tumor necrosis factor alpha (TNF-α) is critical in both of them ([@bib36]).

Dorsal root ganglion (DRG) neurons play an essential role in detecting the changes in the external environment. As a pseudounipolar neuron, its peripheral axon branches transfer different forms of sensory stimuli into action potentials (APs) and its central axon branches conduct the APs to spinal dorsal horn ([@bib4]). Activation of voltage-gated sodium (Na~v~) channels is indispensable for the initiation and conduction of APs. Among the nine subunits of Na~v~ channels ([@bib3]), tetrodotoxin-sensitive (TTX-S) channels Na~v~1.3, Na~v~1.6, and Na~v~1.7 and TTX-resistant (TTX-R) channels Na~v~1.8 and Na~v~1.9 are proved important for the excitability of DRG neurons ([@bib8]). Previous works show that activation of TNF-α/NF-κB signaling leads to chronic hyperexcitability of DRG neurons ([@bib13], [@bib15], [@bib34], [@bib39]) and of cortical neurons ([@bib5]) by transcriptional upregulation of sodium channels. In the present work, we provided evidence that *p*-p65 also enhances Na^+^ currents in a transcription-independent way. The data uncover a novel mechanism by which TNF-α/NF-κB signaling rapidly regulates cell excitability.

Results {#sec2}
=======

*p*-p65 (s311) Is Located in the Membrane of DRG Neurons, and Reducing Cytoplasmic *p*-p65 Inhibits Na^+^ Currents within Minutes {#sec2.1}
---------------------------------------------------------------------------------------------------------------------------------

Immunofluorescent staining showed that *p*-p65 (s311) was located not only in the nucleus but also in the membrane of DRG neurons in both naive and neuropathic rats, namely, vincristine (VCR, a chemotherapeutic agent)-induced peripheral neuropathy or lumbar 5 spinal nerve ligation (L5-SNL) ([Figures 1](#fig1){ref-type="fig"}A--1C). Western blots with membrane protein extract of DRGs revealed that the membrane *p*-p65 level was significantly higher in either VCR-treated or L5-SNL rats compared with vehicle-treated or sham-operated rats ([Figures 1](#fig1){ref-type="fig"}D and 1E). Double staining showed that *p*-p65 (s311) was colocalized with the markers of large neurons (NF-200) and of small neurons (CGRP and IB4) but not with the marker of satellite glial cells (GFAP) ([Figure 1](#fig1){ref-type="fig"}F). We quantified the levels of *p*-p65 in large (NF-200 positive) and small (NF-200 negative) DRG neurons. As shown in [Figures 1](#fig1){ref-type="fig"}G and 1H, the total gray value of *p*-p65 signal in large neurons was higher than that in small neurons, but the average gray value of *p*-p65 signal (total gray value/cell area) in large neurons was lower than that in small neurons. The data indicate that *p*-p65 is expressed in all types of DRG neurons, although expression is more intensive in small ones. Therefore, in the following experiments all sizes of DRG neurons were used.Figure 1Phospho-p65 (s311) Is Located in the Membrane of Dorsal Root Ganglion Neurons and Is Increased in Neuropathic Conditions(A--C) The representative confocal images show that *p*-p65 is located not only in the nucleus but also in the membrane of DRG neurons in naive (A), vincristine (VCR)-treated (B) and L5-spinal nerve ligation (L5-SNL) (C) rats. Scale bars: left 100 μm, right 20 μm.(D and E) The western blots show that *p*-p65 in membrane is increased in VCR-treated (D) and L5-SNL (E) rats, compared with vehicle and sham rats. Samples were harvested after the last VCR injection or 10 days after L5-SNL. n = 6 in each group. ∗∗p \< 0.01, ∗∗∗p \< 0.001 compared with vehicle or sham group.(F) The cell types that express *p*-p65 (s311) in DRG neurons. Scale bars: 50 μm.(G and H) The total (G) and the average (H) gray value of *p*-p65 signal in NF-200 positive (larger-diameter) and NF-200-negative (small-diameter) neurons. n = 40 in NF200-negative group, n = 62 in NF200-positive group. ∗∗∗p \< 0.001 compared with the corresponding NF200-negative group. Two-tailed t test. The specificity of the antibody for *p*-p65 (s311) was identified in [Figure S2](#mmc1){ref-type="supplementary-material"}A. Data expressed as mean ± SD. The control of membrane fractionation process was shown in [Figure S2](#mmc1){ref-type="supplementary-material"}C.

The primary function of DRG neurons is production of APs in response to various sensory stimuli, and opening of Na~v~ channels is critical in this process. We, therefore, tested if membrane *p*-p65 might regulate the Na~v~ channels. To do this, total Na^+^, TTX-S, or TTX-R currents were recorded in the DRG neurons of VCR-treated rats with microelectrodes containing *p*-p65 antibody (10 μg/mL) or IgG. TTX-S and TTX-R currents were isolated by blocking TTX-R channels with A-803467 (1 μM) ([@bib42]) ([Figure S1](#mmc1){ref-type="supplementary-material"}) and by blocking TTX-S channels with TTX (300 nM), respectively. As shown in [Figures 2](#fig2){ref-type="fig"}A--2C, compared with IgG control group, a significant reduction of total Na^+^, TTX-S, or TTX-R currents was evident at 6, 3, and 18 min after the onset of recordings. The results indicate that *p*-p65 facilitates Na~v~ currents. To confirm this, pyrrolidinedithiocarbamate (PDTC, 10 nM), an NF-κB inhibitor that reduces intracellular *p*-p65 by inhibition of IκB-ubiquitin ligase activity ([@bib12]), was applied extracellularly 1 min after recordings. We found that PDTC inhibited total Na^+^ currents, TTX-S currents, or TTX-R currents within 6--9 min, compared with the vehicle group ([Figures 2](#fig2){ref-type="fig"}D--2F). We found that both intracellular anti-*p*-p65 and extracellular PDTC preferably inhibited TTX-S currents over TTX-R ones ([Figures 2](#fig2){ref-type="fig"}G and 2H).Figure 2Intracellular Application of Anti-*p*-p65 (s311) or Extracellular Application of PDTC Preferably Reduces TTX-S Na^+^ Currents over TTX-R Ones within Minutes(A--C) The effects of intracellular anti-*p*-p65 (10 μg/mL) on total (A), TTX-S (B) and TTX-R (C) Na^+^ currents. The raw traces were recorded immediately on onset (black) and 18 min (red) after recordings. n = 6 in each group. ∗p \< 0.05, ∗∗∗p \< 0.001 compared with the corresponding IgG group. (D--F) The effects of extracellular NF-κB inhibitor PDTC (10 nM) on total (D), TTX-S (E) and TTX-R (F) Na^+^ currents. The raw traces were recorded immediately on onset (black) and 18 min (red) after recordings. n = 6 in each group. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001 compared with the corresponding vehicle group.(G and H) The histograms show the inhibitory rates of anti-*p*-p65 (G) and PDTC (H) on total, TTX-S, and TTX-R currents at 18 min after recordings. ∗p \< 0.05, ∗∗p \< 0.01 compared with total currents; ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001 compared with TTX-S currents. A-F, two-way repeated measures ANOVA followed by Bonferroni\'s multiple comparisons test; G and H, one-way ANOVA followed by Holm-Sidak\'s multiple comparisons test. Data expressed as mean ± SD.

Membrane *p*-p65 Gates Na~v~1.7 Channels by Protein-Protein Interaction {#sec2.2}
-----------------------------------------------------------------------

Our data that *p*-p65 was located in the membrane and that PDTC inhibited Na~v~ currents within minutes suggested that *p*-p65 might regulate Na~v~ channels, non-transcriptionally. To investigate the mechanisms underlying the rapid effect, we tested the possibility that *p*-p65 may gate sodium channels by protein-protein interaction. The co-immunoprecipitation (Co-IP) experiments with the protein extract of DRGs from VCR-treated rats showed that *p*-p65 interacted potently with Na~v~1.7, weakly with Na~v~1.6, and barely with Na~v~1.3, Na~v~1.8, or Na~v~1.9 ([Figures 3](#fig3){ref-type="fig"}A--3F). To confirm the *p*-p65-Na~v~1.7 interaction, we performed high-resolution images of structured illumination microscopy and found that 69.4 ± 11.1% of Na~v~1.7 was colocalized with *p*-p65, whereas only 30.3 ± 4.3% of *p*-p65 was colocalized with Na~v~1.7 in membrane of DRG neurons from VCR-treated rats ([Figures 3](#fig3){ref-type="fig"}G and 3H).Figure 3*p*-p65 (s311) Interacts with Na~v~1.7 Channels in the Membrane of DRG Neurons(A--F) Co-IP with DRG protein extract of VCR-treated rats shows that *p*-p65 strongly interacted with Na~v~1.7 (C and F), weakly with Na~v~1.6 (B), but not with Na~v~1.3 (A), Na~v~1.8 (D), or Na~v~1.9 (E).(G) The structured illumination microscopies show that *p*-p65 is colocalized with Na~v~1.7 in DRG neuron membrane of VCR rat. Scale bars: left 10 μm, right 5 μm.(H) Quantification data show colocalization rates of Na~v~1.7 with *p*-p65 (colocalized yellow spots/total Na~v~1.7 positive spots) and those of *p*-p65 with Na~v~1.7 (colocalized yellow spots/total *p*-p65 positive spots) in membrane. n = 4 in each group. ∗∗∗p \< 0.001 compared with Na~v~1.7 with *p*-p65 group. The specificity of the antibody for Na~v~1.7 was identified ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Two-tailed t test. Data expressed as mean ± SD.

We then investigated the effect of the interaction on TTX-S Na~v~1.7 channels. If *p*-p65 was required for activation of Na~v~1.7 channels, blockade of Na~v~1.7 would occlude the inhibitory effect of PDTC on TTX-S currents as shown in [Figures 2](#fig2){ref-type="fig"}D--2F. Indeed, we found that PDTC (10 nM) failed to affect TTX-S currents when applied 15 min after extracellular application of ProTxII (5 nM), a selective Na~v~1.7 blocker ([@bib30]), in DRG neurons of VCR-treated rats ([Figures 4](#fig4){ref-type="fig"}A and 4B). Conversely, ProTxII also failed to affect TTX-S Na^+^ currents when applied 15 min after PDTC ([Figures 4](#fig4){ref-type="fig"}C and 4D). To further study the effect of *p*-p65 on Na~v~1.7 channels, we repeated the experiments with ICA-121431 (5 μM), a potent rat Na~v~1.7 channel blocker (IC~50~: 37 nM) ([@bib21]), and found that the effects of ICA-121431 and PDTC on TTX-S currents were also occluded by each other ([Figures 4](#fig4){ref-type="fig"}E--4H). In addition, we found that intracellular application of anti-*p*-p65 also blocked the inhibitory effect of ProTxII on TTX-S currents ([Figures 4](#fig4){ref-type="fig"}I and 4J). The mutual inhibition between PDTC and Na~v~1.7 blockers on TTX-S currents was also observed in the DRG neurons from naive rats ([Figures 5](#fig5){ref-type="fig"}A--5H).Figure 4NF-κB Inhibitor PDTC Inhibits Na~v~1.7 Channels by Reducing Na~v~1.7- *p*-p65 Interaction in Membrane of DRG Neurons(A) The traces show TTX-S currents recorded in indicated conditions.(B) ProTxII (5 nM) occludes the effect of PDTC (10 nM) on TTX-S currents of VCR rats. n = 7. ∗∗∗p \< 0.001 compared with predrug control.(C) The traces show TTX-S currents recorded in indicated conditions.(D) PDTC (10 nM) occludes the effect of ProTxII (5 nM) on TTX-S currents of VCR rats. n = 6. ∗∗∗p \< 0.001 compared with predrug control.(E) The traces show TTX-S currents recorded in indicated conditions.(F) ICA121431 (5 μM) occludes the effect of PDTC on TTX-S currents of VCR rats. n = 6. ∗∗∗p \< 0.001 compared with predrug control.(G) The traces show TTX-S currents recorded in indicated conditions.(H) PDTC occludes the effect of ICA121431 on TTX-S currents of VCR rats. n = 6. ∗p \< 0.05, ∗∗∗p \< 0.001 compared with predrug control.(I) The traces show TTX-S currents recorded in indicated conditions.(J) Intracellular application of anti-*p*-p65 blocks the effect of ProTxII on TTX-S currents of VCR rats. n = 6. ∗∗∗p \< 0.001 compared with the first recording.(K and L) Thirty minutes after intrathecal injection of PDTC (15 μg/10 μL), both *p*-p65 (K) and Na~v~1.7 (L) in the membrane were tested. n = 6 in each group. ∗p \< 0.05, ∗∗∗p \< 0.001 compared with vehicle group; ^\#\#^p \< 0.01 compared with VCR group.(M) The membrane Na~v~1.7 in DRGs of naive rats was measured 30 min after intrathecal injection of PDTC (15 μg/10 μL). n = 6 in each group.(N) The interaction between *p*-p65 and Na~v~1.7 in DRGs of VCR-treated rats was reduced 30 min after intrathecal injection of PDTC (15 μg/10 μL). Na~v~1.7 was immunoprecipitated by *p*-p65 antibody. n = 3 in each group. ∗∗∗p \< 0.001 compared with VCR + vehicle group.(O and P) Intrathecal injection of PDTC (10 μL) dose-dependently reduced *p*-p65 levels in both membrane (P) and cytoplasm (O). The DRG tissues were harvested 30 min after injection. n = 4 in each group. ∗p \< 0.05, ∗∗∗p \< 0.001 compared with VCR + vehicle group. B, D, F, H, J, K, L, O, P, one-way ANOVA followed by Tukey\'s multiple comparisons test. M, N, Two-tailed t test. Data expressed as mean ± SD. N.S. mean not significant.Figure 5The Effects of PDTC and Na~v~1.7 Blockers on TTX-S Channels Occlude Each Other in DRG Neurons of Naive Rats(A) The traces show TTX-S currents recorded in indicated conditions.(B) ProTxII blocks the effect of PDTC on TTX-S currents. n = 6. ∗∗p \< 0.01, ∗∗∗p \< 0.001 compared with predrug control.(C) The traces show TTX-S currents recorded in indicated conditions.(D) PDTC blocks the effect of ProTxII on TTX-S currents. n = 6. ∗∗∗p \< 0.001 compared with predrug control.(E) The traces show TTX-S currents recorded in indicated conditions.(F) ICA-121431 occludes the effect of PDTC on TTX-S currents. n = 6. ∗∗∗p \< 0.001 compared with predrug control.(G) The traces show TTX-S currents recorded in indicated conditions.(H) PDTC blocks the effect of ICA-121431 on TTX-S currents. n = 6. ∗p \< 0.05, ∗∗∗p \< 0.001 compared with predrug control. B, D, F, H, one-way ANOVA followed by Tukey\'s multiple comparisons test. Data expressed as mean ± SD. N.S. mean not significant.

To investigate how reducing intracellular *p*-p65 decreases Na~v~1.7 currents, we measured *p*-p65 and Na~v~1.7 in DRG membrane from VCR- and vehicle-treated rats. The western blots with membrane protein extract of DRGs revealed that both *p*-p65 and Na~v~1.7 were significantly increased in the VCR-treated group compared with the vehicle-treated group. Importantly, intrathecal injection of PDTC reduced *p*-p65 but did not affect Na~v~1.7 in cell membrane within 30 min ([Figures 4](#fig4){ref-type="fig"}K and 4L). The results indicate that the inhibitory effect of extracellular PDTC or intracellular anti-*p*-p65 on Na^+^ currents is due to the reduction of *p*-p65 but not of Na~v~1.7 in cell membrane. We found that PDTC also did not affect membrane Na~v~1.7 in DRGs of naive rats ([Figure 4](#fig4){ref-type="fig"}M). Our data that PDTC rapidly reduces TTX-S Na^+^ currents and membrane *p*-p65 suggested that the interaction between *p*-p65 and Na~v~1.7 in membrane might be reversible, depending on its intracellular content. To test this, we performed Co-IP with DRGs from VCR-treated rats and found that the *p*-p65-Na~v~1.7 interaction was substantially reduced 30 min after intrathecal injection of PDTC ([Figure 4](#fig4){ref-type="fig"}N). Consistently, intrathecal injection of PDTC reduced *p*-p65 in both cytoplasm and membrane dose-dependently ([Figures 4](#fig4){ref-type="fig"}O and 4P). The data indicate that *p*-p65 may regulate Na~v~1.7 channels by reversible interaction with the channel subtype.

TNF-α Enhances Membrane *p*-p65 (s311) and Na~v~1.7 Currents within Minutes in Cultured DRG Neurons {#sec2.3}
---------------------------------------------------------------------------------------------------

To test if nuclear transcription may also contribute to the rapid effect of *p*-p65 on Na~v~1.7 channels, we performed the experiments with cultured DRG neurons. As TNF-α plays a key role in both classical and alternative NF-κB activation pathways ([@bib36]), we incubated DRG neurons from naive rats with rat recombinant TNF-α (rrTNF-α, 100 ng/mL) and measured *p*-p65 levels in membrane and in nuclei at different time points afterward. A significant increase of *p*-p65 was detected in membrane within 5 min ([Figure 6](#fig6){ref-type="fig"}A), whereas in nuclei at 120 min but not within 40 min ([Figures 6](#fig6){ref-type="fig"}B and 6C). That is, in response to TNF-α stimulation, *p*-p65 membrane translocation is at least 40 min earlier than its nuclear translocation. Furthermore, we found that rrTNF-α did not affect membrane Na~v~1.7 level within 20 min ([Figure 6](#fig6){ref-type="fig"}D) but enhanced Na~v~1.7 currents, isolated by subtraction of the ProTxII-resistant Na^+^ currents from total Na^+^ currents ([@bib18]), within 5 min. The I-V curves ([Figure 6](#fig6){ref-type="fig"}E) showed that the peak Na~v~1.7 currents in the DRG neurons treated with rrTNF-α (100 ng/mL for 5 min) were significantly higher, compared with the neurons treated with the vehicle. To test if the effect of rrTNF-α on Na~v~1.7 currents is mediated by membrane *p*-p65, DRG neurons were incubated with rrTNF-α for 5 min and then with PDTC (10 nM) for 15 min. The peak currents in the rrTNF-α + PDTC group were significantly lower compared with the rrTNF-α alone group and were not different from the vehicle group ([Figure 6](#fig6){ref-type="fig"}E). Therefore, the rapid effect of TNF-α on Na~v~1.7 channels results from the *p*-p65-Na~v~1.7 interaction and is independent of *p*-p65 nuclear transcription and the membrane Na~v~1.7 level. To investigate the potential mechanism by which *p*-p65 regulates Na~v~1.7 currents, we performed experiments with HEK293 cells that express Na~v~1.7. The results showed that PDTC accelerated inactivation and delayed recovery but did not affect activation of Na~v~1.7 channels ([Figures 6](#fig6){ref-type="fig"}F--6H and [Table 1](#tbl1){ref-type="table"}). In consistence with the electrophysiological data, we found that intrathecal injection of PDTC alleviated the decrease in mechanical pain thresholds induced by VCR within 30 min ([Figure 6](#fig6){ref-type="fig"}I).Figure 6TNF-α Enhances Membrane *p*-p65 (s311) and Na~v~1.7 Currents in Cultured DRG Neurons without Affecting Nuclear *p*-p65 and Membrane Na~v~1.7 within Minutes(A--D) The western blots show the levels of *p*-p65 and Na~v~1.7 in membrane (A and D) or nucleus (B and C) of DRG neurons at indicated time points after application of rrTNF-α (100 ng/mL). n = 6 in each group. ∗∗∗p \< 0.001 compared with vehicle group.(E) The I-V curves show the peak Na~v~1.7 currents recorded under different potentials in indicated groups. n = 9, 8, and 9 in control, TNF-α, and TNF-α + PDTC group.(F--H) The effects of PDTC (10 nM) on activation (F), inactivation (G), and recovery (H) of Na~v~1.7 channels in HEK293 cells. n = 6--7 in each group.(I) Intrathecal injection of NF-κB inhibitor PDTC (10 μL) reduces mechanical allodynia in vincristine (VCR)-treated rats within 30 min. n = 5 in each group. ∗∗∗p \< 0.001 compared with vehicle + VCR group. The data in A, B, C, D, and E were analyzed with one-way ANOVA followed by Tukey\'s multiple comparisons test, and in F, G, and H with two-tailed t test. I, two-way repeated measures ANOVA followed by Bonferroni\'s multiple comparisons test. Data expressed as mean ± SD. The control of nuclear fractionation process was shown in [Figure S2](#mmc1){ref-type="supplementary-material"}C.Table 1The Effects of PDTC on the Parameters of Activation, Inactivation, and Recovery of Na~v~1.7 Channels in HEK293 CellsActivationInactivationRecoveryV~0.5~kV~0.5~kτControl−33.6 ± 3.45.7 ± 1.7−77.6 ± 2.55.4 ± 0.24.5 ± 0.8PDTC−34.8 ± 3.66.6 ± 1.0−84.0 ± 2.3[a](#tblfn1){ref-type="table-fn"}5.1 ± 0.49.2 ± 3.3[b](#tblfn2){ref-type="table-fn"}[^3][^4][^5]

Discussion {#sec3}
==========

As mentioned in the [Introduction](#sec1){ref-type="sec"} section, NF-κB plays important roles in many physiological and pathological processes. Up to date, all the functions of NF-κB are explained by its transcriptional effect. In this present work, we showed for the first time that *p*-p65 was also located in the membrane of DRG neurons and was increased in neuropathic conditions *in vivo* or in response to TNF-α stimulation in cultured DRG neurons. The membrane *p*-p65 regulated Na~v~1.7 channels by protein-protein interaction. In membrane of DRG neurons, ∼70% of Na~v~1.7 was colocalized with *p*-p65, whereas only ∼30% of *p*-p65 is colocalized with Na~v~1.7 ([Figure 3](#fig3){ref-type="fig"}H). The data suggested that *p*-p65 might also regulate cell function by interacting with other proteins in cell membranes. Further studies are needed to elucidate this issue. We also found that reduction of cytoplasmic *p*-p65 by intracellular anti-*p*-p65 or extracellular PDTC also inhibited TTX-R currents. As no interaction between *p*-p65 and TTX-R channels (Na~v~1.8 and Na~v~1.9) in DRG neurons was detected, the mechanisms underlying the effect remains elusive.

On activation, Na~v~ channels go through rapid transitions from the resting to opening, inactivated state and eventually recover to the resting state ([@bib1]). Na~v~1.7 is distinguished from other TTX-S channels by slow closed-state inactivation, which is suggested to determine action potential threshold by permitting to pass a current in response to small slow depolarization (see [@bib7] for a review). Our data showed that PDTC reduced Na~v~1.7-*p*-p65 interaction ([Figure 4](#fig4){ref-type="fig"}N) and accelerated inactivation and delayed recovery but did not affect activation of Na~v~1.7 channels ([Figures 6](#fig6){ref-type="fig"}F--6H and [Table 1](#tbl1){ref-type="table"}). That is, *p*-p65-Na~v~1.7 interaction may increase Na~v~1.7 currents by slowing inactivation and facilitating recovery from inactivation, leading to an increase of the resting state of Na~v~1.7 that is ready for opening.

Previous works show that NF-κB is expressed at the synapses and neuromuscular junction and in neuronal fibers, and the local NF-κB is also believed to regulate gene expression ([@bib9], [@bib23], [@bib29]). The synaptic NF-κB is also speculated to function locally. Up to date, however, no direct evidence is available in vertebrate ([@bib29]). In drosophila, it has been shown that Dorsal (homolog of NF-κB) in neuromuscular junction regulates glutamate receptor density in a transcription-independent way ([@bib14]).

Na~v~1.7 has been intensively studied in the sensory system. In human, loss of function of Na~v~1.7 leads to complete inability to sense pain ([@bib6]) and odors ([@bib37]), whereas gain of its function results in paroxysmal extreme pain disorder ([@bib10]). In rodents, deletion of Na~v~1.7 in mouse DRG neurons attenuates acute nociception and nerve injury-, inflammation- and burn injury-induced pain hypersensitivity ([@bib25], [@bib24], [@bib27], [@bib31]). Blockage of Na~v~1.7 significantly alleviates neuropathic pain induced by the chemotherapeutic drug paclitaxel ([@bib18]). A recent study shows that mutation of Na~v~1.7 in human patients leads to functional absence of nociceptors ([@bib22]). Accordingly, Na~v~1.7 is a prominent target for treating chronic pain. Our finding that *p*-p65 gates Na~v~1.7 channels in naive and neuropathic rats raises a possibility that selective blockage of the interaction between *p*-p65 and Na~v~1.7 channels may treat the chronic pain resulting from gain of Na~v~1.7 function. The new strategy can avoid the side effects of NF-κB inhibitor owing to its transcriptional inhibition.

In addition, global deletion of Na~v~1.7 in mice leads to death shortly after birth ([@bib27]), indicating that the channel subtype should play important roles in other vital systems. Consistently, Na~v~1.7 is found in the brain regions that regulate autonomic and endocrine systems of rats ([@bib26]) and in airway parasympathetic ganglia of mice, guinea pig, and human ([@bib17]). Furthermore, Na~v~1.7 is also expressed in human immature dendritic cells ([@bib41]). Na~v~1.7 expressed in gastric cancer cells and human non-small cell lung cancer cells promotes cancer progression or invasion ([@bib2], [@bib38]). It is interesting to know if NF-κB also non-transcriptionally regulates the Na~v~1.7 in these cells.

It has been well established that TNF-α produces a persistent hyperexcitability through gene transcription in DRG ([@bib13], [@bib15], [@bib34], [@bib39]) and in cortical neurons ([@bib5]). TNF-α has also been repeatedly demonstrated to induce an acute excitation of DRG neurons ([@bib20], [@bib40]) and of subfornical organ neurons ([@bib32]). TNF-α enhances sodium currents in DRG neurons within minutes ([@bib16]). The mechanism underlying the rapid effect is unknown. Our result that *p*-p65 regulates Na~v~1.7 channels by protein-protein interaction may explain the TNF-α-induced acute excitation. A previous work shows that NF-κB in DRG neurons is activated by noxious electrical, chemical, and thermal stimulation of peripheral tissues within minutes, and the physiological significance of this rapid NF-κB activation is not clarified ([@bib11]). We propose that NF-κB may rapidly regulate somatosensory function via gating of ion channels in DRG neurons.

Together, activation of TNF-α/NF-κB signaling induces not only the chronic hypersensitivity of DRG neurons by nuclear transcription but also an acute excitation of the neurons by protein-protein interaction. In this process, NF-κB functions not only as a transcription factor but also as an ion channel modulator. Our finding may open up a new arena for investigating mechanisms by which NF-κB regulates cell functions.

Limitations of the Study {#sec3.1}
------------------------

We explored that *p*-p65 rapidly regulates Na~v~1.7 by protein-protein interaction in DRG neurons, whereas the mechanism underlying the interaction was not investigated. NF-κB is also highly expressed in the neurons of the central nervous system and is activated by basal synaptic transmission, glutamate, and depolarization ([@bib19], [@bib23]). Whether it also non-transcriptionally regulates the functions of the central neurons remains elusive.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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